Brokerages Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Price Target at $13.17

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) has been given a consensus recommendation of “Moderate Buy” by the six research firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $13.17.

Several research analysts have recently weighed in on the stock. HC Wainwright lifted their price target on shares of Fulcrum Therapeutics from $14.00 to $17.00 and gave the stock a “buy” rating in a research note on Wednesday, February 28th. Piper Sandler upped their target price on shares of Fulcrum Therapeutics from $13.00 to $15.00 and gave the stock an “overweight” rating in a report on Wednesday, February 28th. Royal Bank of Canada assumed coverage on Fulcrum Therapeutics in a research note on Wednesday, March 13th. They issued an “outperform” rating and a $14.00 price target for the company. Finally, The Goldman Sachs Group boosted their price objective on Fulcrum Therapeutics from $5.00 to $6.00 and gave the company a “neutral” rating in a research report on Thursday, January 25th.

Insider Buying and Selling at Fulcrum Therapeutics

In other Fulcrum Therapeutics news, VP Greg Tourangeau sold 4,884 shares of the business’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $11.72, for a total value of $57,240.48. Following the sale, the vice president now owns 11,807 shares in the company, valued at approximately $138,378.04. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 2.50% of the stock is currently owned by insiders.

Institutional Trading of Fulcrum Therapeutics

A number of large investors have recently added to or reduced their stakes in FULC. Legal & General Group Plc boosted its position in shares of Fulcrum Therapeutics by 8.3% during the 4th quarter. Legal & General Group Plc now owns 13,925 shares of the company’s stock valued at $101,000 after acquiring an additional 1,066 shares during the last quarter. Amalgamated Bank raised its stake in Fulcrum Therapeutics by 42.1% during the fourth quarter. Amalgamated Bank now owns 5,724 shares of the company’s stock valued at $42,000 after purchasing an additional 1,696 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in Fulcrum Therapeutics by 2.4% during the first quarter. Charles Schwab Investment Management Inc. now owns 72,209 shares of the company’s stock valued at $1,708,000 after purchasing an additional 1,724 shares during the last quarter. Northern Trust Corp lifted its position in Fulcrum Therapeutics by 1.4% during the fourth quarter. Northern Trust Corp now owns 144,965 shares of the company’s stock valued at $979,000 after purchasing an additional 1,984 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its stake in shares of Fulcrum Therapeutics by 13.4% in the 4th quarter. The Manufacturers Life Insurance Company now owns 17,020 shares of the company’s stock worth $124,000 after buying an additional 2,009 shares in the last quarter. Institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Price Performance

Shares of Fulcrum Therapeutics stock opened at $7.36 on Tuesday. The company’s fifty day simple moving average is $9.61 and its 200-day simple moving average is $6.79. The stock has a market capitalization of $455.84 million, a PE ratio of -4.66 and a beta of 2.29. Fulcrum Therapeutics has a 1-year low of $2.42 and a 1-year high of $13.70.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its quarterly earnings results on Tuesday, February 27th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.04. The business had revenue of $0.87 million for the quarter, compared to analysts’ expectations of $0.65 million. Fulcrum Therapeutics had a negative net margin of 3,470.05% and a negative return on equity of 36.65%. As a group, research analysts anticipate that Fulcrum Therapeutics will post -1.76 EPS for the current year.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.